Supplemental NDA for stronger version of Advair deemed "not approvable"

Share this article:
A GlaxoSmithKline supplemental NDA for a stronger version of asthma drug Advair Diskus for use in treating patients with chronic obstructive pulmonary disease, recommended for approval by an FDA advisory committee, has been deemed “not approvable” in another apparent show of agency independence from its outside panels.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"